123 related articles for article (PubMed ID: 25641349)
1. Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series.
Marshall A; Li A; Drucker A; Dzik W
Hematol Oncol; 2016 Sep; 34(3):147-53. PubMed ID: 25641349
[TBL] [Abstract][Full Text] [Related]
2. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies.
Juhl RC; Roddy JVF; Wang TF; Li J; Elefritz JL
Leuk Lymphoma; 2018 Oct; 59(10):2377-2382. PubMed ID: 29424601
[TBL] [Abstract][Full Text] [Related]
4. The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial.
Verma K; Errico T; Diefenbach C; Hoelscher C; Peters A; Dryer J; Huncke T; Boenigk K; Lonner BS
J Bone Joint Surg Am; 2014 May; 96(10):e80. PubMed ID: 24875032
[TBL] [Abstract][Full Text] [Related]
5. Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: Four adult case reports and a review of the literature.
Buckley LF; Reardon DP; Camp PC; Weinhouse GL; Silver DA; Couper GS; Connors JM
Heart Lung; 2016; 45(3):232-6. PubMed ID: 26907195
[TBL] [Abstract][Full Text] [Related]
6. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid.
Bartholomew JR; Salgia R; Bell WR
Arch Intern Med; 1989 Sep; 149(9):1959-61. PubMed ID: 2774776
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
Penta de Peppo A; Pierri MD; Scafuri A; De Paulis R; Colantuono G; Caprara E; Tomai F; Chiariello L
Tex Heart Inst J; 1995; 22(3):231-6. PubMed ID: 7580360
[TBL] [Abstract][Full Text] [Related]
8. Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients.
Garewal HS; Durie BG
Scand J Haematol; 1985 Nov; 35(5):497-500. PubMed ID: 4089529
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Study of 122 Dogs That Were Treated with the Antifibrinolytic Drug Aminocaproic Acid: 2010-2012.
Davis M; Bracker K
J Am Anim Hosp Assoc; 2016; 52(3):144-8. PubMed ID: 27008326
[TBL] [Abstract][Full Text] [Related]
10. Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia?
Chakrabarti S; Varma S; Singh S; Kumari S
Eur J Haematol; 1998 May; 60(5):313-4. PubMed ID: 9654162
[No Abstract] [Full Text] [Related]
11. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic Acid on coronary artery bypass surgery without cardiopulmonary bypass.
Gurian DB; Meneghini A; Abreu LC; Murad N; Matos LL; Pires AC; Valenti VE; Breda JR
Clin Appl Thromb Hemost; 2014 Sep; 20(6):615-20. PubMed ID: 23434921
[TBL] [Abstract][Full Text] [Related]
12. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia.
Gardner FH; Helmer RE
JAMA; 1980 Jan; 243(1):35-7. PubMed ID: 6965311
[TBL] [Abstract][Full Text] [Related]
13. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage.
Kalmadi S; Tiu R; Lowe C; Jin T; Kalaycio M
Cancer; 2006 Jul; 107(1):136-40. PubMed ID: 16708357
[TBL] [Abstract][Full Text] [Related]
14. Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders.
Kaye JD; Smith EA; Kirsch AJ; Cerwinka WH; Elmore JM
J Urol; 2010 Sep; 184(3):1152-7. PubMed ID: 20650477
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis.
Gunawan B; Runyon B
Aliment Pharmacol Ther; 2006 Jan; 23(1):115-20. PubMed ID: 16393288
[TBL] [Abstract][Full Text] [Related]
16. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage.
Starke RM; Kim GH; Fernandez A; Komotar RJ; Hickman ZL; Otten ML; Ducruet AF; Kellner CP; Hahn DK; Chwajol M; Mayer SA; Connolly ES
Stroke; 2008 Sep; 39(9):2617-21. PubMed ID: 18658042
[TBL] [Abstract][Full Text] [Related]
17. Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Ford PA; Grant SJ; Mick R; Keck G
J Clin Oncol; 2015 May; 33(15):1674-9. PubMed ID: 25870085
[TBL] [Abstract][Full Text] [Related]
18. Long-term Complications and Management of Gastrointestinal Bleeding in Multifocal Lymphangioendotheliomatosis.
Shakir AK; Yu Z; Altaf MA
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e534-e537. PubMed ID: 30334900
[TBL] [Abstract][Full Text] [Related]
19. Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery.
Scott JP; Costigan DJ; Hoffman GM; Simpson PM; Dasgupta M; Punzalan R; Berens RJ; Tweddell JS; Stuth EA
J Clin Anesth; 2014 May; 26(3):204-11. PubMed ID: 24809789
[TBL] [Abstract][Full Text] [Related]
20. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients.
Bush SP; Seifert SA; Oakes J; Smith SD; Phan TH; Pearl SR; Reibling ET
Toxicon; 2013 Jul; 69():29-37. PubMed ID: 23474267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
